Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2946)
All Articles published online
|
Jul 7, 2006 (publication date) through Dec 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhang YC, Wang XP, Zhang LY, Song AL, Kou ZM, Li XS. Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells. World J Gastroenterol 2006; 12(25): 3977-3982 [PMID: 16810743 DOI: 10.3748/wjg.v12.i25.3977] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i25/3977.htm |
| Number | Citing Articles |
| 1 |
WEN-ZHOU DING, QING-FENG NI, YE-TING LU, LIANG-LIANG KONG, JIAN-JUN YU, LONG-WEI TAN, LIAN-BAO KONG. MicroRNA-497 regulates cell proliferation in hepatocellular carcinoma. Oncology Letters 2016; 11(2): 1081 doi: 10.3892/ol.2015.3981
|
| 2 |
Mengke Niu, Ming Yi, Ning Li, Kongju Wu, Kongming Wu. Advances of Targeted Therapy for Hepatocellular Carcinoma. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.719896
|
| 3 |
Christèle Desbois-Mouthon, Aurore Baron, Marie-José Blivet-Van Eggelpoël, Laetitia Fartoux, Corinne Venot, Friedhelm Bladt, Chantal Housset, Olivier Rosmorduc. Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma. Clinical Cancer Research 2009; 15(17): 5445 doi: 10.1158/1078-0432.CCR-08-2980
|
| 4 |
Vladimir M. Subbotin. Privileged portal metastasis of hepatocellular carcinoma in light of co-evolution of a visceral portal system and the liver in the chordate lineage: a search for therapeutic targets. Drug Discovery Today 2018; 23(3): 548 doi: 10.1016/j.drudis.2018.01.020
|
| 5 |
Aldona Kasprzak, Wojciech Kwasniewski, Agnieszka Adamek, Anna Gozdzicka-Jozefiak. Insulin-like growth factor (IGF) axis in cancerogenesis. Mutation Research/Reviews in Mutation Research 2017; 772: 78 doi: 10.1016/j.mrrev.2016.08.007
|
| 6 |
Aldona Kasprzak, Agnieszka Adamek, Wiesława Przybyszewska, Przemysław Pyda, Jacek Szmeja, Agnieszka Seraszek-Jaros, Agata Lanzafame, Anna Surdacka, Iwona Mozer-Lisewska, Maria Koczorowska. Insulin-like growth factor-1 mRNA isoforms and insulin-like growth factor-1 receptor mRNA expression in chronic hepatitis C. World Journal of Gastroenterology 2015; 21(13): 3867-3875 doi: 10.3748/wjg.v21.i13.3867
|
| 7 |
Ghassan K. Abou-Alfa, Marinela Capanu, Eileen M. O’Reilly, Jennifer Ma, Joanne F. Chou, Bolorsukh Gansukh, Jinru Shia, Marcia Kalin, Seth Katz, Leslie Abad, Diane L. Reidy-Lagunes, David P. Kelsen, Helen X. Chen, Leonard B. Saltz. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. Journal of Hepatology 2014; 60(2): 319 doi: 10.1016/j.jhep.2013.09.008
|
| 8 |
Angela M Liu, Michelle Z Xu, Jinfei Chen, Ronnie T Poon, John M Luk. Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opinion on Therapeutic Targets 2010; 14(8): 855 doi: 10.1517/14728222.2010.499361
|
| 9 |
Frans van Valen, Henning Harrer, Marc Hotfilder, Uta Dirksen, Thomas Pap, George Gosheger, Hans-Ulrich Humpf, Heribert Jürgens. A Novel Role of IGF1 in Apo2L/TRAIL-Mediated Apoptosis of Ewing Tumor Cells. Sarcoma 2012; 2012: 1 doi: 10.1155/2012/782970
|
| 10 |
JINGJING ZHU, WIM VAN DE VEN, ALPHONS VERMORKEN. Polyphenols with indirect proprotein convertase inhibitory activity. International Journal of Oncology 2013; 43(3): 947 doi: 10.3892/ijo.2013.2009
|
| 11 |
Yasushi Adachi, Masanori Nojima, Mitsuru Mori, Yasutaka Matsunaga, Noriyuki Akutsu, Shigeru Sasaki, Takao Endo, Youichi Kurozawa, Kenji Wakai, Akiko Tamakoshi. Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study. Tumor Biology 2016; 37(11): 15125 doi: 10.1007/s13277-016-5360-z
|
| 12 |
Mónica Enguita-Germán, Puri Fortes. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World Journal of Hepatology 2014; 6(10): 716-737 doi: 10.4254/wjh.v6.i10.716
|
| 13 |
ALDONA KASPRZAK, AGNIESZKA ADAMEK. The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (Review). International Journal of Oncology 2012; 41(6): 1919 doi: 10.3892/ijo.2012.1666
|
| 14 |
Cai Qun Bie, Xu You Liu, Ming Rong Cao, Qiu Yan Huang, Hui Jun Tang, Min Wang, Guo Li Cao, Ting Zhuang Yi, Sheng Lan Wu, Wei Jie Xu, Shao Hui Tang. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression. Oncotarget 2016; 7(48): 79305 doi: 10.18632/oncotarget.13027
|
| 15 |
XIAO HONG BAO, YOSHIO NAOMOTO, HUI FANG HAO, NOBUYUKI WATANABE, KAZUFUMI SAKURAMA, KAZUHIRO NOMA, TAKAYUKI MOTOKI, YASUKO TOMONO, TAKUYA FUKAZAWA, YASUHIRO SHIRAKAWA, TOMOKI YAMATSUJI, JUNJI MATSUOKA, MUNENORI TAKAOKA. IGF-IR and its inhibitors in gastrointestinal carcinomas (Review). Oncology Letters 2010; 1(1): 195 doi: 10.3892/ol_00000036
|
| 16 |
JING KONG, ZHENYU DIAO, XIAOZHAO DENG. Inhibition of IGF receptor signaling and hepatoma cell growth by an antibody to ligand oligopeptide of receptor. Growth Factors 2008; 26(1): 35 doi: 10.1080/08977190801987315
|
| 17 |
Xiuli Liu, Wei Jiang, Federico Aucejo, Richard Kim, Charles Miller, Michael Byrne, Rocio Lopez, Lisa Yerian. Insulin-like growth factor I receptor β expression in hepatocellular carcinoma. Human Pathology 2011; 42(6): 882 doi: 10.1016/j.humpath.2010.10.007
|
| 18 |
S Whittaker, R Marais, A X Zhu. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29(36): 4989 doi: 10.1038/onc.2010.236
|
| 19 |
Anthony B. El-Khoueiry, Robert O’Donnell, Thomas J. Semrad, Philip Mack, Suzette Blanchard, Nathan Bahary, Yixing Jiang, Yun Yen, John Wright, Helen Chen, Heinz-Josef Lenz, David R. Gandara. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology 2018; 81(5): 957 doi: 10.1007/s00280-018-3553-4
|